Prelude Therapeutics Incorporated (PRLD) News
Follow Prelude Therapeutics Incorporated (PRLD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Prolight Diagnostics Receives First SEK 19.9M Purchase Order
The order from BRAINBox is under a 2026 supply agreement and covers commercial products ahead of BRAINBox’s planned US TBI launch using Prolight’s Psyros platform.
EQUITY | Oct 28, 2026, 07:00 AM UTC
L
Prelude, Lilly to Evaluate PRT13722 in Breast Cancer Trial
Prelude announced a clinical trial collaboration and supply agreement with Lilly to evaluate its KAT6A selective degrader PRT13722 alongside Verzenio and Inluriyo in patients with HR+/HER2- breast cancer.
EQUITY | Oct 13, 2026, 11:01 AM UTC
M
Prelude Therapeutics clears FDA to start Phase 1 trial
The company received FDA clearance to proceed with a Phase 1 study of oral KAT6A degrader PRT13722. It expects patient enrollment in 4Q 2026.
EQUITY | Sep 10, 2026, 11:33 AM UTC
M
Prolight Diagnostics signs BRAINBox supply agreement worth $3.9 million
Prolight Diagnostics signed a supply agreement with BRAINBox valued at USD 3.9 million during the first year, according to an article published by BioStock.
EQUITY | Sep 08, 2026, 06:16 AM UTC
M
Prolight signs supply agreement with BRAINBox valued at USD 3.9M first year
Prolight Diagnostics AB (publ) said it signed a supply agreement with BRAINBox Solutions for instruments and cartridges. Anticipated first-year supply post FDA clearance and market launch is valued at USD 3.9 million.
REGULATION | Sep 07, 2026, 05:30 AM UTC
M
PRLD secures SEK 29M BRAINBox deal
PRLD secured a SEK 29M deal with BRAINBox, citing improved cash flow and narrower losses tied to strong TBI results.
EQUITY | Aug 27, 2026, 01:02 PM UTC
L
Prolight Diagnostics publishes half-year report for 2026
Prolight Diagnostics has published its half-year report for 2026.
EQUITY | Aug 27, 2026, 01:00 PM UTC
L
Prelude Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Prelude Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
EARNINGS | Aug 11, 2026, 07:18 PM UTC
H
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Tuesday. Shares of Sherwin-Williams Co (NYSE: SHW ) rose sharply after the company reported better-than-expected second-quarter financial resu
EARNINGS | Jul 28, 2026, 02:05 PM UTC
L
PRLD +20% in pre-mkt INCY - Prelude Therapeutics shares are higher in pre-mkt after Incyte discontinues further development of INCB160058. [
PRLD +20% in pre-mkt INCY - Prelude Therapeutics shares are higher in pre-mkt after Incyte discontinues further development of INCB160058. [Prelude Therapeutics' corresponding drug candidate is PRT12396, a mutant-selecti
EQUITY | Jul 28, 2026, 12:53 PM UTC